Resources Repository
-
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Cost-Effectiveness Analysis | Decision Analysis | Health Outcomes | Costing Methods | Evidence Synthesis | Benefit-Cost Analysis | Policy/Regulation | Health/Medicine | Global | Graduate | Doctoral | Professional -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Decision Analysis | Health Outcomes | Costing Methods | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Calibration/Validation | Dynamic Simulation | Infectious Diseases | Health/Medicine -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Health Outcomes | Costing Methods | Evidence Synthesis | Chronic Disease/Risk | Health/Medicine | Global -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Cost-Effectiveness Analysis | Decision Analysis | Health Outcomes | Preferences/Values | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | North America | Europe -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Decision Analysis | Health Outcomes | Evidence Synthesis | Mathematical Models | Health Systems | Policy/Regulation | Health/Medicine | North America -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Technology Assessment | Health/Medicine | North America -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health Outcomes | Costing Methods | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Cost-Effectiveness Analysis | Decision Theory | Priority Setting/Ethics | Value of Information | Economics/Finance | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America